Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Product, net	$ 5,421
Revenue from research contracts and other grants		$ 1,253	$ 9,757
Total revenues	5,421	1,253	9,757
Cost and expenses:
Cost of sales	130
Research and development	188,272	146,394	94,231
Selling, general and administrative	83,749	75,043	49,315
Total cost and expenses	272,151	221,437	143,546
Operating loss	(266,730)	(220,184)	(133,789)
Other (loss) income:
Interest (expense) income and other, net	(535)	154	779
Loss on change in warrant valuation	0	0	(2,779)
Total other (loss) income	(535)	154	(2,000)
Net loss	(267,265)	(220,030)	(135,789)
Other comprehensive loss:
Unrealized loss on short-term securities - available-for-sale	(9)	(16)	(95)
Total other comprehensive loss	(9)	(16)	(95)
Comprehensive loss	$ (267,274)	$ (220,046)	$ (135,884)
Net loss per share — basic and diluted	$ (5.49)	$ (5.20)	$ (3.39)
Weighted average number of shares of common stock outstanding for computing basic and diluted net loss per share	48,697	42,290	40,026